A GLP-1 Recall or Counterfeit Alert: Check the Exact Product

When a GLP-1 package looks wrong, the first useful task is describing the item and the concern. We would make a short product record before calling, so the pharmacist can consider the label, packaging and delivery details together.⁷

Identify the signal before drawing a conclusion

A recall concerns removing a defective drug from the market or warning about a potential risk. Match the notification to your medicine.¹

A counterfeit alert concerns a product represented as authentic. Its identifying details and exceptions matter.²

A warning letter communicates FDA’s concerns to a recipient and gives an opportunity to respond. Read its scope rather than treating the letter itself as a recall notice.⁵

An adverse-event report describes an occurrence after a medicine was taken. That timing alone does not establish the cause.⁸

Make one record of the package you received

Photograph the outer carton, pen or vial label, dispensing label and any damaged component. Write down the medicine name, presentation, stated strength, lot or batch, serial number if present, expiration or beyond-use date, pharmacy and delivery date. Keep the receipt and explain what changed or looked wrong. FDA accepts product-quality concerns about packaging, labeling, contamination, stability and suspect counterfeits; symptoms are not the only reason to raise a concern.⁷

Match the notice to the product, not just its name

FDA advises checking the medicine’s lot against the recall notification. Read the full notice for the company, product, presentation and applicable instructions. A headline about semaglutide does not tell you that every semaglutide product is included. Ask the dispensing pharmacist to resolve a missing or unclear identifier rather than treating a partial match as the answer. Not all recalls receive public announcements. A search without a match therefore does not certify your medicine’s safety.¹

A genuine lot number is not authentication

In a dated December 5, 2025 example, FDA described counterfeit Ozempic injection 1 mg bearing PAR1229, also an authentic lot number. The notice distinguishes EXP/LOT text placement and an exception for authentic product from Novo Nordisk’s Patient Assistance Program. This historical example explains why the complete alert matters; it is not a universal test for every pen, a current recall declaration or authentication of your package.²

Keep the presentation and packaging together

Novo Nordisk’s Ozempic pen FAQ shows comparisons of pens, needle packaging and cartons. Use the material for the particular product it describes; a pen comparison cannot authenticate a compounded vial. The manufacturer asks people with a product problem to retain the product and packaging until speaking with its customer-care team. That lets the discussion concern the actual item rather than a description reconstructed after disposal.³

The same FAQ lists live product support at 1-866-696-4090, Monday–Friday, 8:30 a.m.–6 p.m. Eastern. Describe the exact presentation and problem. Ask who will assess the item and what product-handling steps apply. Keeping a package does not guarantee replacement, and neither a complaint nor a photograph establishes a refund entitlement.³

For a compounded product, confirm the named pharmacy

FDA has identified fraudulent compounded GLP-1 labels naming nonexistent pharmacies or a licensed pharmacy that did not make the product. Contact the pharmacy named on your dispensing information through independently checked contact details. Ask whether it prepared and dispensed that prescription and whether it has a matching batch notice. Our pharmacy verification guide explains the identity check; a familiar pharmacy name alone does not authenticate the contents.⁴

A warning letter needs its own reading

A warning letter communicates FDA’s concerns and gives the recipient an opportunity to respond. It may concern manufacturing, promotion or directions rather than a particular patient’s vial. FDA explains that later communications can change the status of the issues and that verified corrections may support a closeout letter. Read the dated finding and any available follow-up; do not turn the existence of a letter into an assumed current recall or a verdict on your individual medicine.⁵

Report the concern without waiting for a diagnosis

MedWatch accepts serious reactions, quality problems and product-use errors involving human medical products. FDA encourages discussing a serious reaction with a health professional, who can supply clinical information from the record. Consumers can also make a voluntary report themselves. Start at FDA’s official reporting information page, and keep a copy or reference number for follow-up. Reporting and asking the seller about a commercial remedy are different tasks.⁶

Reporting helps investigation; it does not prove cause

FDA distinguishes an adverse event from an adverse drug reaction: an event after treatment need not have been caused by it. Its safety reviewers examine reports alongside other evidence. Report what happened and the relevant timing without presenting your suspicion as a confirmed cause. A report count is not a personal risk estimate, and a dashboard is not a comparison of which seller supplied the safer preparation.⁸

Keep treatment continuity with the prescribing team

Contact the prescribing clinician separately about the concern and any potential interruption. Ask whom to contact while the pharmacy investigates. Our missed-dose and restart guide helps organize that conversation; this product-checking workflow does not supply a replacement regimen or instructions to change treatment. If the original issue was temperature, our warm-shipment guide keeps that separate assessment in view.⁴